Mycenax Biotech Inc. (TPEX:4726)

Mycenax Biotech Statistics

Total Valuation

Mycenax Biotech has a market cap or net worth of TWD 5.63 billion. The enterprise value is 6.59 billion.

Market Cap	5.63B
Enterprise Value	6.59B

Important Dates

The next estimated earnings date is Monday, August 10, 2026.

Earnings Date	Aug 10, 2026
Ex-Dividend Date	n/a

Share Statistics

Mycenax Biotech has 207.23 million shares outstanding. The number of shares has increased by 0.46% in one year.

Current Share Class	207.23M
Shares Outstanding	207.23M
Shares Change (YoY)	+0.46%
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	1.37%
Owned by Institutions (%)	0.19%
Float	115.85M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.90
PB Ratio	3.78
P/TBV Ratio	3.90
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-15.11
EV / Sales	8.09
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-40.03

Financial Position

The company has a current ratio of 0.62, with a Debt / Equity ratio of 0.80.

Current Ratio	0.62
Quick Ratio	0.29
Debt / Equity	0.80
Debt / EBITDA	n/a
Debt / FCF	-7.19
Interest Coverage	-12.37

Financial Efficiency

Return on equity (ROE) is -25.79% and return on invested capital (ROIC) is -8.65%.

Return on Equity (ROE)	-25.79%
Return on Assets (ROA)	-7.20%
Return on Invested Capital (ROIC)	-8.65%
Return on Capital Employed (ROCE)	-19.40%
Weighted Average Cost of Capital (WACC)	5.84%
Revenue Per Employee	2.11M
Profits Per Employee	-1.13M
Employee Count	387
Asset Turnover	0.24
Inventory Turnover	8.19

Taxes

Income Tax	-8.32M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -28.93% in the last 52 weeks. The beta is 0.43, so Mycenax Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.43
52-Week Price Change	-28.93%
50-Day Moving Average	29.69
200-Day Moving Average	33.30
Relative Strength Index (RSI)	32.47
Average Volume (20 Days)	299,481

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mycenax Biotech had revenue of TWD 815.34 million and -436.48 million in losses. Loss per share was -2.11.

Revenue	815.34M
Gross Profit	-161.98M
Operating Income	-384.83M
Pretax Income	-444.80M
Net Income	-436.48M
EBITDA	-140.33M
EBIT	-384.83M
Loss Per Share	-2.11

Balance Sheet

The company has 217.52 million in cash and 1.18 billion in debt, with a net cash position of -967.21 million or -4.67 per share.

Cash & Cash Equivalents	217.52M
Total Debt	1.18B
Net Cash	-967.21M
Net Cash Per Share	-4.67
Equity (Book Value)	1.49B
Book Value Per Share	7.17
Working Capital	-510.87M

Cash Flow

In the last 12 months, operating cash flow was -67.55 million and capital expenditures -97.16 million, giving a free cash flow of -164.71 million.

Operating Cash Flow	-67.55M
Capital Expenditures	-97.16M
Depreciation & Amortization	244.51M
Net Borrowing	112.04M
Free Cash Flow	-164.71M
FCF Per Share	-0.79

Margins

Gross margin is -19.87%, with operating and profit margins of -47.20% and -53.53%.

Gross Margin	-19.87%
Operating Margin	-47.20%
Pretax Margin	-54.55%
Profit Margin	-53.53%
EBITDA Margin	-17.21%
EBIT Margin	-47.20%
FCF Margin	n/a

Dividends & Yields

Mycenax Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.46%
Shareholder Yield	-0.46%
Earnings Yield	-7.76%
FCF Yield	-2.93%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Mycenax Biotech has an Altman Z-Score of 1.75 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.75
Piotroski F-Score	4